Telix Receives FDA's Fast Track Designation For Its BiPASS Program To Trace Prostate Cancer Prior To Biopsy

Telix Pharmaceuticals has been granted Fast Track designation by the FDA for its BiPASS program, which aims to enhance imaging for prostate cancer prior to biopsy. This designation is intended to expedite the development and review process for the program, potentially leading to quicker access for patients. The stock ticker for Telix is TLX.